牛牛AI助理已提取核心訊息
David Young, the President of Research & Development at Processa Pharmaceuticals, Inc. [PCSA], completed a purchase of 20,000 shares of common stock on February 6, 2024. The transaction was carried out on the open market at a price of $2.5252 per share. Following this acquisition, Young's direct holdings in the company increased to 58,387 shares. Additionally, Young has indirect holdings totaling 60,315 shares, which are held through the Young-Plaisance Revocable Trust, Family Entities, and CorLyst, LLC.
David Young, the President of Research & Development at Processa Pharmaceuticals, Inc. [PCSA], completed a purchase of 20,000 shares of common stock on February 6, 2024. The transaction was carried out on the open market at a price of $2.5252 per share. Following this acquisition, Young's direct holdings in the company increased to 58,387 shares. Additionally, Young has indirect holdings totaling 60,315 shares, which are held through the Young-Plaisance Revocable Trust, Family Entities, and CorLyst, LLC.
Processa Pharmicals, Inc. [PCSA] 研發總裁大衛·楊於2024年2月6日完成了對2萬股普通股的購買。該交易在公開市場上進行，價格爲每股2.5252美元。此次收購後，楊在公司的直接持股量增加到58,387股。此外，楊的間接持股總額爲60,315股，這些股票通過Young-Plaisance可撤銷信託、家族實體和CorlyST, LLC持有。
Processa Pharmicals, Inc. [PCSA] 研發總裁大衛·楊於2024年2月6日完成了對2萬股普通股的購買。該交易在公開市場上進行，價格爲每股2.5252美元。此次收購後，楊在公司的直接持股量增加到58,387股。此外，楊的間接持股總額爲60,315股，這些股票通過Young-Plaisance可撤銷信託、家族實體和CorlyST, LLC持有。
有用
沒用